179 related articles for article (PubMed ID: 36485142)
1. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
Covut F; Sanfilippo KM
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
[TBL] [Abstract][Full Text] [Related]
2. Assessing the risk of venous thromboembolism in multiple myeloma.
Sanfilippo KM
Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
Frenzel L; Decaux O; Macro M; Belhadj-Merzoug K; Manier S; Touzeau C; Leleu X; Frère C; Lecompte T; Perrot A; Avet-Loiseau H; Moreau P; Chalayer E
Thromb Res; 2024 Jan; 233():153-164. PubMed ID: 38064842
[TBL] [Abstract][Full Text] [Related]
5. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort.
da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
J Thromb Thrombolysis; 2023 Jul; 56(1):147-155. PubMed ID: 37133703
[TBL] [Abstract][Full Text] [Related]
7. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
8. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.
Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF
Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000
[TBL] [Abstract][Full Text] [Related]
9. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study.
Bao L; Fang LJ; Xiao MY; Lu MQ; Chu B; Shi L; Gao S; Xiang QQ; Wang YT; Liu X; Ding YH; Xin Z; Chen Y; Wang MZ; Hu WK; Guo CY; Chen LY; Sun K
Thromb Res; 2024 Apr; 236():130-135. PubMed ID: 38430904
[TBL] [Abstract][Full Text] [Related]
10. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
[TBL] [Abstract][Full Text] [Related]
11. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
[TBL] [Abstract][Full Text] [Related]
12. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
Leleu X; Rodon P; Hulin C; Daley L; Dauriac C; Hacini M; Decaux O; Eisemann JC; Fitoussi O; Lioure B; Voillat L; Slama B; Al Jijakli A; Benramdane R; Chaleteix C; Costello R; Thyss A; Mathiot C; Boyle E; Maloisel F; Stoppa AM; Kolb B; Michallet M; Lamblin A; Natta P; Facon T; Elalamy I; Fermand JP; Moreau P
Thromb Haemost; 2013 Oct; 110(4):844-51. PubMed ID: 23903204
[TBL] [Abstract][Full Text] [Related]
13. Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.
Takaishi K; Tsukamoto S; Ohwada C; Takeuchi M; Kawasaki Y; Nagai Y; Mishina T; Yamazaki M; Isshiki Y; Kayamori K; Kimura K; Hino Y; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Iseki T; Nakaseko C; Sakaida E
J Thromb Thrombolysis; 2019 Jul; 48(1):141-148. PubMed ID: 30673940
[TBL] [Abstract][Full Text] [Related]
14. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Carrier M; Le Gal G; Tay J; Wu C; Lee AY
J Thromb Haemost; 2011 Apr; 9(4):653-63. PubMed ID: 21255254
[TBL] [Abstract][Full Text] [Related]
15. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.
Li A; Wu Q; Luo S; Warnick GS; Zakai NA; Libby EN; Gage BF; Garcia DA; Lyman GH; Sanfilippo KM
J Natl Compr Canc Netw; 2019 Jul; 17(7):840-847. PubMed ID: 31319391
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Baljevic M; Sborov DW; Lim MY; Hillengass J; Martin T; Castillo JJ; Streiff MB; Kumar SK; Callander NS
J Natl Compr Canc Netw; 2022 Jan; 20(1):91-95. PubMed ID: 34991076
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations.
Swan D; Rocci A; Bradbury C; Thachil J
Br J Haematol; 2018 Nov; 183(4):538-556. PubMed ID: 30450656
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
